Glenmark Pharmaceuticals

Organisation

Trials

NCT02179645
Collaborator, Phase 1, Completed, 76 people, 2 Jul 2014

Named in competing interests

Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
Consulting or advice, Fees or honoraria, Grants or research support, 13 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

Papers

Twenty-Five Years Longitudinal Real-World Analysis of Statin Therapy Outcomes in People with Diabetes on Telemedicine Follow-up and Predictors of Cardiovascular Events
ADA Scientific Sessions 2025 abstract, 13 Jun 2025